Mode
Text Size
Log in / Sign up
Phase 3 Completed N=221 Randomized Double-blind Treatment

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

Source: ClinicalTrials.gov NCT03657810 ↗
Enrolled (actual)
221
Serious AEs
0.4%
Results posted
Mar 2023
Primary outcomePrimary: Percentage of Participants With OINV Over 48 Hours — 8; 31; 4 Participants — p=<0.001
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With OINV Over 48 Hours
8; 31; 4 <0.001 sig
PRIMARY
The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48)
108.5; 94.8; 78.7 0.052
SECONDARY
Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours
50; 34; 27
SECONDARY
Percentage of Patients With Any Vomiting Over 48 Hours
3; 19; 2
SECONDARY
Percentage of Patients With Any Nausea Over 48 Hours
36; 55; 15
SECONDARY
Percentage of Patients With Any Nausea or Vomiting Over 48 Hours
37; 55; 16
SECONDARY
Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV)
9; 12; 6
SECONDARY
Number of Doses of Study Medication Taken Over Days 3to7
10.0; 8.4; 6.2
SECONDARY
Number of Doses of Study Medication Taken Per Day Over Days 3to7
3.0; 2.4; 2.1; 2.1; 1.9; 1.4

Eligibility Criteria

Inclusion Criteria

  • Informed consent: Signed informed consent form obtained at screening prior to any procedures being performed.
  • Gender: Male or non-pregnant and non-lactating female.
  • Age: 18 years or older at time of consent.
  • Foot condition: Primary unilateral first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
  • Pain Severity: Presence of moderate or severe pain on a categorical pain intensity scale at Baseline
  • Pain Confirmation: On the 0-10 numerical pain intensity scale at Baseline.
  • Diary Completion: Be willing and able to record safety and efficacy ratings in the Diaries.
  • Safe Transportation Home: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult.

Exclusion Criteria

  • Medical condition: Presence of a serious medical condition, intolerance to NSAIDs, or any other medical condition which, in the opinion of the Investigator, makes the patient unsuitable for participation.
  • Infection: Acute infection of the surgical site at the time of surgery that could confound post-surgical evaluation.
  • Drug Allergy: History of hypersensitivity to an opioid drug (such as hydrocodone), promethazine, acetaminophen, NSAID (such as ibuprofen or aspirin), midazolam, propofol, mepivacaine, ropivacaine or ketorolac.
  • Confounding and Contraindicated Drugs: Other than protocol-permitted medications administered pre-operatively or during surgery: use within 14 days before or during the surgical procedure of any systemic corticosteroid or use within 24 hours or during the surgical procedure of any confounding prescription or non-prescription drug or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. [Note: Antibiotic for endocarditis prophylaxis (except if known to cause nausea) and aspirin (ASA) ≤ 325 mg for cardiovascular prophylaxis are permitted during the study.] History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test for opiates, benzodiazepines, barbiturates, tetrahydrocannabinol, methamphetamines, cocaine, oxycodone, cotinine at screening or the morning of surgery will exclude the patient from the trial.
  • Investigational Drug Use: Use of an investigational drug within the past 30 days.
  • Participated in Study: Previous participation in this study.
  • Pregnancy, Lactation: Women who are pregnant or lactating.
  • Compliance: Inability to swallow capsules whole.
  • Participant relationship: Employee at the research center, employee of the Principal Investigator, Sub-Investigators, or sponsor or relative of the Investigator, Sub-Investigators or research staff who is involved in this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03657810). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search